<DOC>
	<DOCNO>NCT00855465</DOCNO>
	<brief_summary>The aim study assess efficacy safety different dose BAY63-2521 , give orally 16 week , patient Chronic Thromboembolic Pulmonary Hypertension ( CTEPH ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Oral BAY63-2521 Patients With CTEPH .</brief_title>
	<detailed_description>Adverse event data cover Adverse event section .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Male female patient CTEPH either inoperable persistent recurrent PH surgery . All type pulmonary hypertension except subtypes 4.1 4.2 Venice Clinical Classification Pulmonary Hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>soluble Guanylate Cyclase Stimulator</keyword>
	<keyword>sGC</keyword>
</DOC>